Deal News | Acquisition of Pentapharm AG

Orlando Capital V successfully completes acquisition of Pentapharm AG and its sister company Pentapharm do Brasil Comércio e Exportação Ltda.

• Pentapharm is a leading provider of biological active ingredients for pharmaceutical and diagnostic applications, with unique expertise in hemostasis
• The company employs around 120 people at its locations in Aesch (CH) and Uberlândia (BR)
• Complex carve-out transaction from the dsm-firmenich group

Munich / Aesch, July 25, 2025 – Orlando Capital V has successfully completed the acquisition of Pentapharm AG, a specialized provider of active pharmaceutical ingredients (APIs), diagnostic products, and natural cosmetic ingredients. This marks the second platform acquisition by Orlando Capital V in 2025 and the sixth by the fund in the past 18 months.

Founded in 1948 in Basel, Pentapharm has a corporate history spanning more than 75 years. In 2007, the company was acquired by dsm-firmenich. As part of a strategic realignment, dsm-firmenich decided to carve out and divest Pentapharm. The sale process was led by C.H. Reynolds Corporate Finance.

Pentapharm has established itself as a reliable partner for numerous renowned companies in the pharmaceutical, diagnostics, and cosmetics industries. In the pharmaceutical sector, the company offers biological APIs for blood coagulation management, which are used particularly in coagulation disorders and surgical applications. The diagnostics portfolio includes a broad range of products for hemostasis diagnostics – including ready-to-use test kits, substrates, inhibitors, biochemical reagents, and enzymes derived from snake venom. In addition, Pentapharm develops and manufactures natural bioactive ingredients for cosmetic applications in the skincare segment.

Transaction Structure

As part of the transaction, Orlando Capital V is acquiring 100% of the shares in Pentapharm AG. In collaboration with the existing management team, the company’s independence will be strengthened, and international business development further expanded. We thank dsm-firmenich for the trust placed in us throughout this transaction and look forward to the future collaboration with dsm-firmenich as a reliable and valued partner in the cosmetics ingredients business.

Simon Pfennigsdorf, Partner at Orlando Capital, commented: “Pentapharm is an exceptional company with unique capabilities and an impressive history. We look forward to strategically and operationally developing the company together with the experienced management team and expanding its leading role as a highly specialized provider of biological active ingredients. We are convinced that in an independent setup, Pentapharm can unleash further entrepreneurial potential to successfully expand its business in all three segments.”

About Orlando Capital

Orlando Capital V is a private equity firm based in Munich, primarily active in the German-speaking region and the Nordic countries. We manage the private equity fund Orlando Capital V with a fund volume of €255 million. Our investment focus is on majority stakes in well-positioned medium-sized companies – particularly in succession situations, complex carve-outs, and special situations. With 25 years of experience, the Orlando team has successfully advised on more than 85 transactions, emphasizing trusting relationships and entrepreneurial partnerships with owners and sellers.